Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient received the first and second doses of Vivotif every other day, however, the patient took the third dose on sunday instead of saturday; Case reference number US-BN-2024-002230 is a spontaneous case initially received from pharmacist via Med Communications (reference number: USBAV24-1728) on 22-Jul-2024 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for typhoid immunization. On an unspecified date, reported as every other day after the first dose, the patient took the second dose of Vivotif (batch number: unknown), at an unknown dose, orally. On 21-Jul-2024, reported as on Sunday, the patient took the third dose of Vivotif (batch number: unknown), at an unknown dose, orally. As reported, the patient took the third dose on Sunday instead of Saturday (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: A patient of unknown age and gender took the third dose of Vivotif for typhoid immunization. As reported, the patient took the third dose on Sunday instead of Saturday, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown age and gender took the third dose of Vivotif for typhoid immunization. As reported, the patient took the third dose on Sunday instead of Saturday, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.